Citation: | GE Fan, WANG Wen-kai, ZHU Jing-tian, LI Zi-hang, SUN Yue, XUE Mei. Astragaloside Ⅳ Regulates Blood Lipid and Inflammatory Factors Through NLRP3 Inflammasome in Early Diabetic Atherosclerosis Rats[J]. Journal of Nanjing University of traditional Chinese Medicine, 2021, 37(3): 383-387. doi: 10.14148/j.issn.1672-0482.2021.0383 |
[1] |
李晓龙, 高青青, 李博, 等. 瑞芬太尼介导 AMPKα1/PGC-1α/GLUT4 通路对糖尿病动脉粥样硬化大鼠血脂和炎症的调节作用[J]. 西部医学, 2020, 32(2): 182-188. doi: 10.3969/j.issn.1672-3511.2020.02.006
|
[2] |
XUE M, BIAN Y, LIU YL, et al. Danggui Buxue decoction ameliorates lipid metabolic defects involved in the initiation of diabetic atherosclerosis; identification of active compounds[J]. J Tradit Chin Med, 2020, 40(3): 414-421. http://www.cnki.com.cn/Article/CJFDTotal-ZYYW202003009.htm
|
[3] |
CHEN YY, WEN SY, JIANG MM, et al. Atherosclerotic dyslipidemia revealed by plasma lipidomics on ApoE-/- mice fed a high-fat diet[J]. Atherosclerosis, 2017, 262: 78-86. doi: 10.1016/j.atherosclerosis.2017.05.010
|
[4] |
ROM O, GRAJEDA-IGLESIAS C, NAJJAR M, et al. Atherogenicity of amino acids in the lipid-laden macrophage model system in vitro and in atherosclerotic mice: A key role for triglyceride metabolism[J]. J Nutr Biochem, 2017, 45: 24-38. doi: 10.1016/j.jnutbio.2017.02.023
|
[5] |
POZNYAK A, GRECHKO AV, POGGIO P, et al. The diabetes mellitus-atherosclerosis connection: The role of lipid and glucose metabolism and chronic inflammation[J]. Int J Mol Sci, 2020, 21(5): E1835. doi: 10.3390/ijms21051835
|
[6] |
ZAHID A, LI B, KOMBE AJK, et al. Pharmacological inhibitors of the NLRP3 inflammasome[J]. Front Immunol, 2019, 10: 2538. doi: 10.3389/fimmu.2019.02538
|
[7] |
ZHAO C, ZHAO W. NLRP3 inflammasome: A key player in antiviral responses[J]. Front Immunol, 2020, 11: 211. doi: 10.3389/fimmu.2020.00211
|
[8] |
SHARMA A, CHOI JSY, STEFANOVIC N, et al. Specific NLRP3 inhibition protects against diabetes-associated atherosclerosis[J]. Diabetes, 2021, 70(3): 772-787. doi: 10.2337/db20-0357
|
[9] |
TAN YQ, CHEN HW, LI J. Astragaloside Ⅳ: An effective drug for the treatment of cardiovascular diseases[J]. Drug Des Devel Ther, 2020, 14: 3731-3746. doi: 10.2147/DDDT.S272355
|
[10] |
袁艳萍, 郑志娟, 李运伦. 黄芪甲苷改善心血管疾病中内皮机制的研究进展[J/OL]. 中华中医药学刊, 2020: 1-15. http://kns.cnki.net/kcms/detail/21.1546.R.20201106.1748.072.html.
|
[11] |
王文恺, 孙悦, 钟琪, 等. 当归补血汤对糖尿病合并抑郁症模型大鼠血清炎症因子的干预作用[J]. 中医学报, 2020, 35(6): 1258-1261. https://www.cnki.com.cn/Article/CJFDTOTAL-HNZK202006033.htm
|
[12] |
王文恺, 张蔚, 孙悦, 等. 当归补血汤及其主要活性成分阿魏酸对糖尿病抑郁症模型大鼠的影响及机制研究[J]. 中药新药与临床药理, 2020, 31(6): 649-654. https://www.cnki.com.cn/Article/CJFDTOTAL-ZYXY202006007.htm
|
[13] |
王文恺, 张良, 孙悦, 等. 当归补血汤治疗糖尿病抑郁症的研究进展[J]. 世界科学技术-中医药现代化, 2018, 20(12): 2191-2195.
|
[14] |
王春艳, 宋礼. 盐酸贝那普利联合比索洛尔对高血压合并冠心病患者血脂及炎性因子水平影响[J]. 社区医学杂志, 2019, 17(18): 1120-1123. https://www.cnki.com.cn/Article/CJFDTOTAL-SQYX201918008.htm
|
[15] |
王春葆. 盐酸贝那普利联合比索洛尔对高血压合并冠心病患者血压、血脂、血管内皮功能和炎症因子水平的影响分析[J]. 中国实用医药, 2020, 15(1): 124-125. https://www.cnki.com.cn/Article/CJFDTOTAL-ZSSA202001058.htm
|
[16] |
SPROSTON NR, ASHWORTH JJ. Role of C-reactive protein at sites of inflammation and infection[J]. Front Immunol, 2018, 9: 754. doi: 10.3389/fimmu.2018.00754
|
[17] |
ZELOVÁ H, HOŠEK J. TNF-α signalling and inflammation: Interactions between old acquaintances[J]. Inflamm Res, 2013, 62(7): 641-651. doi: 10.1007/s00011-013-0633-0
|
[18] |
PEDERSEN BK. Anti-inflammatory effects of exercise: Role in diabetes and cardiovascular disease[J]. Eur J Clin Invest, 2017, 47(8): 600-611. http://citeseerx.ist.psu.edu/viewdoc/download?doi=10.1.1.690.6083&rep=rep1&type=pdf
|
[19] |
KELLEY N, JELTEMA D, DUAN YH, et al. The NLRP3 inflammasome: An overview of mechanisms of activation and regulation[J]. Int J Mol Sci, 2019, 20(13): E3328. doi: 10.3390/ijms20133328
|
[20] |
LENG WL, OUYANG XS, LEI XT, et al. The SGLT-2 inhibitor dapagliflozin has a therapeutic effect on atherosclerosis in diabetic ApoE-/- mice[J]. Mediators Inflamm, 2016, 2016: 6305735. http://downloads.hindawi.com/journals/mi/2016/6305735.pdf
|